CytoMed Therapeutics Limited

GDTC · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$1,843-$3,132-$2,338-$1,521
Dep. & Amort.$246$289$293$245
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$58-$4-$108-$321
Other Non-Cash-$39$256$1,048$328
Operating Cash Flow-$1,984-$2,676-$1,044-$1,270
Investing Activities
PP&E Inv.-$1,025-$44-$354-$432
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$2,063$0-$180
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$1,520$1$0$1
Investing Cash Flow$495-$2,106-$353-$611
Financing Activities
Debt Repay.-$33-$31-$59-$44
Stock Issued$0$8,418$1,104$2,976
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1-$223-$252$162
Financing Cash Flow-$33$8,165$793$3,094
Forex Effect-$42$73-$30-$24
Net Chg. in Cash-$1,277$3,537-$684$1,193
Supplemental Information
Beg. Cash$4,717$1,179$1,863$670
End Cash$3,439$4,717$1,179$1,863
Free Cash Flow-$3,010-$2,720-$1,398-$1,702
CytoMed Therapeutics Limited (GDTC) Financial Statements & Key Stats | AlphaPilot